Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension
暂无分享,去创建一个
N. Voelkel | K. Stenmark | M. Peters-Golden | L. Chung | D. Fiorentino | M. Nicolls | M. Rabinovitch | Rasa Tamosiuniene | A. B. Tu | R. Zamanian | Xinguo Jiang | W. Tian | Eric M Shuffle | Y. Sung | J. Qian | A. Valenzuela | Shirley Y. Jiang | S. Jiang | Eric M. Shuffle | Allen B. Tu | Shirley Y. Jiang | Jin Qian
[1] M. Humbert,et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. , 2015, Chest.
[2] E. Nozik-Grayck,et al. Role of reactive oxygen species in chronic hypoxia-induced pulmonary hypertension and vascular remodeling. , 2007, Advances in experimental medicine and biology.
[3] T. McKinsey,et al. Emergence of Fibroblasts with a Proinflammatory Epigenetically Altered Phenotype in Severe Hypoxic Pulmonary Hypertension , 2011, The Journal of Immunology.
[4] E. Nozik-Grayck,et al. The adventitia: essential regulator of vascular wall structure and function. , 2013, Annual review of physiology.
[5] Yin Xiao,et al. Inhibition of p38 pathway leads to OA-like changes in a rat animal model. , 2012, Rheumatology.
[6] K. Krause,et al. Reactive oxygen species: from health to disease. , 2012, Swiss medical weekly.
[7] E. Spiekerkoetter,et al. Current clinical management of pulmonary arterial hypertension. , 2014, Circulation research.
[8] M. Humbert,et al. Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension , 2014, Circulation.
[9] T. Yue,et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. , 1999, Circulation.
[10] Keisuke Ito,et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells , 2006, Nature Medicine.
[11] S. Sankey,et al. Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. , 2005, Journal of cardiac failure.
[12] A. Anwar,et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[13] W. Busse,et al. The Effect of Inhibition of 5-Lipoxygenase by Zileuton in Mild-to-Moderate Asthma , 1993, Annals of Internal Medicine.
[14] S. Barman,et al. From form to function: the role of Nox4 in the cardiovascular system , 2012, Front. Physio..
[15] K. Griendling,et al. Nox proteins in signal transduction. , 2009, Free radical biology & medicine.
[16] Y. Yun,et al. Sustained expression of NADPH oxidase 4 by p38 MAPK-Akt signaling potentiates radiation-induced differentiation of lung fibroblasts , 2010, Journal of Molecular Medicine.
[17] Yunchao Su,et al. NADPH Oxidase 4 Is Expressed in Pulmonary Artery Adventitia and Contributes to Hypertensive Vascular Remodeling , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[18] D. Welsh,et al. The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension , 2015, American journal of physiology. Lung cellular and molecular physiology.
[19] S. Pullamsetti,et al. Adventitial Fibroblasts Induce a Distinct Proinflammatory/Profibrotic Macrophage Phenotype in Pulmonary Hypertension , 2014, The Journal of Immunology.
[20] J. S. Muhammad,et al. Pulmonary Hypertension in Systemic Sclerosis , 2011 .
[21] C. Long,et al. Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary Hypertension , 2011, Circulation research.
[22] S. Black,et al. Reactive oxygen species in pulmonary vascular remodeling. , 2013, Comprehensive Physiology.
[23] M. Frid,et al. Hypoxia-induced Pulmonary Vascular Remodeling Cellular and Molecular Mechanisms Reviews , 2022 .
[24] E. Mark,et al. Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.
[25] A. Anwar,et al. The adventitia: Essential role in pulmonary vascular remodeling. , 2010, Comprehensive Physiology.
[26] P. ten Dijke,et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. , 2008, Arthritis and rheumatism.
[27] A. Della Corte,et al. Role of myofibroblasts in vascular remodelling: focus on restenosis and aneurysm. , 2010, Cardiovascular research.
[28] K. Stenmark,et al. Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGFβ receptor-JNK1 signalling. , 2012, Cardiovascular research.
[29] T. McKinsey,et al. Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change , 2012, Pulmonary circulation.
[30] T. Cohnert,et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[31] D. Welsh,et al. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. , 2009, American journal of physiology. Heart and circulatory physiology.
[32] M. Peters-Golden,et al. 5-lipoxygenase and FLAP. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.
[33] Jiahuai Han,et al. Activation and signaling of the p38 MAP kinase pathway , 2005, Cell Research.
[34] Jae-Hong Kim,et al. Bioactive lipoxygenase metabolites stimulation of NADPH oxidases and reactive oxygen species , 2011, Molecules and cells.
[35] Manesh R. Patel,et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial , 2014, The Lancet.
[36] J. Molkentin,et al. Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion. , 2005, American journal of physiology. Heart and circulatory physiology.
[37] O. Werz,et al. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[38] H. Schnittler,et al. Nox4 overexpression activates reactive oxygen species and p38 MAPK in human endothelial cells. , 2009, Biochemical and biophysical research communications.
[39] T. Ochiya,et al. Silencing of S100A4, a metastasis-associated protein, in endothelial cells inhibits tumor angiogenesis and growth , 2013, Angiogenesis.
[40] John C. Lee,et al. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. , 1999, Biochemical and biophysical research communications.
[41] David Abraham,et al. Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.
[42] K. Krause,et al. The NADPH oxidase NOX4 drives cardiac differentiation: Role in regulating cardiac transcription factors and MAP kinase activation. , 2006, Molecular biology of the cell.
[43] D. Welsh,et al. Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. , 2001, American journal of respiratory and critical care medicine.
[44] M. Humbert,et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. , 2014, Circulation research.
[45] Duo Wei,et al. p38 mitogen-activated protein kinase inhibition attenuates burn-induced liver injury in rats. , 2005, Burns : journal of the International Society for Burn Injuries.
[46] W. Roberts,et al. Molecular characterization of reactive oxygen species in systemic and pulmonary hypertension. , 2014, American journal of hypertension.
[47] L. Chung,et al. Epidemiology and Risk Factors for Pulmonary Hypertension in Systemic Sclerosis , 2012, Current Rheumatology Reports.
[48] R. Tuder,et al. Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.
[49] I. Wilkinson,et al. Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease , 2014, American Journal of Cardiovascular Drugs.
[50] B. Samuelsson,et al. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. , 2010, Biochemical and biophysical research communications.
[51] Daphne Merkus,et al. Reactive Oxygen Species and the Cardiovascular System , 2013, Oxidative medicine and cellular longevity.
[52] G. Raskob,et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.
[53] L. Howard,et al. Connective tissue disease-associated pulmonary arterial hypertension , 2015, F1000prime reports.
[54] D. Welsh,et al. p38 MAP kinase isoform activity and cell cycle regulators in the proliferative response of pulmonary and systemic artery fibroblasts to acute hypoxia. , 2006, Pulmonary pharmacology & therapeutics.
[55] T. Hirano,et al. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. , 2002, Cytokine & growth factor reviews.
[56] M. A. Moseley,et al. Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S-nitrosylation. , 2012, Free radical biology & medicine.
[57] E. K. Weir,et al. Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.
[58] Vilmundur Gudnason,et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.
[59] K. Stenmark,et al. Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia. , 2008, Cardiovascular research.
[60] D. Welsh,et al. Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. , 2007, American journal of respiratory cell and molecular biology.
[61] M. Peters-Golden,et al. Nuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[62] L. Farkas,et al. Blocking Macrophage Leukotriene B4 Prevents Endothelial Injury and Reverses Pulmonary Hypertension , 2013, Science Translational Medicine.
[63] M. Gladwin,et al. Pulmonary arterial hypertension: the clinical syndrome. , 2014, Circulation research.
[64] Sanjiv J. Shah,et al. Management of Pulmonary Arterial Hypertension , 2015, Seminars in Respiratory and Critical Care Medicine.
[65] J. Gulcher,et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke , 2004, Nature Genetics.
[66] M. Frid,et al. Role of the adventitia in pulmonary vascular remodeling. , 2006, Physiology.